Corrigendum to “Prognosis in advanced lung cancer – A prospective study examining key clinicopathological factors” [Lung Cancer 88 (2015) 304–309] (S0169500215001725) (10.1016/j.lungcan.2015.03.020);Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors

Lung Cancer

Volumn 88, Issue 3, 2015, Pages 304-309

  Simmons, Claribel P ^a   Koinis, Filippos ^b   Fallon, Marie T ^a   Fearon, Kenneth C ^a   Bowden, Jo ^a   Solheim, Tora S ^c   Gronberg, Bjorn Henning ^c,d   McMillan, Donald C ^e   Gioulbasanis, Ioannis ^f   Laird, Barry J ^a,c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f Larisa General Clinic   (Greece)

Author keywords

Cachexia; CRP; Inflammation; Lung cancer; Performance status; Prognosis

Indexed keywords

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CACHEXIA; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; GLASGOW PROGNOSTIC SCORE; HEALTH STATUS; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PERFORMANCE STATUS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SMALL CELL LUNG CANCER; SURVIVAL PREDICTION; SURVIVAL TIME; WEIGHT REDUCTION; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; WEIGHT LOSS;

EID: 84929514291     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.04.015     Document Type: Erratum

References (22)

1. Hagerty R.G., Butow P.N., Ellis P.M., Lobb E.A., Pendlebury S.C., Leighl N., et al. Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis. J Clin Oncol 2005, 23(6):1278-1288. pii:23/6/1278. 10.1200/JCO.2005.11.138.
2. Glare P., Virik K., Jones M., Hudson M., Eychmuller S., Simes J., et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003, 327(7408):195-198. pii:327/7408/195. 10.1136/bmj.327.7408.195.
3. Azzoli C.G., Temin S., Giaccone G. Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract 2012, 8(1):63-66. 10.1200/JOP.2011.000374.
4. Matsuyama R., Reddy S., Smith T.J. Why do patients choose chemotherapy near the end of life?. A review of the perspective of those facing death from cancer. J Clin Oncol 2006, 24(21):3490-3496. pii:24/21/3490. 10.1200/JCO.2005.03.6236.
5. Ross P.J., Ashley S., Norton A., Priest K., Waters J.S., Eisen T., et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?. Br J Cancer 2004, 90(10):1905-1911. pii:6601781. 10.1038/sj.bjc.6601781.
6. Gioulbasanis I., Pallis A., Vlachostergios P.J., Xyrafas A., Giannousi Z., Perdikouri I.E., et al. The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung Cancer 2012, 77(2):383-388. 10.1016/j.lungcan.2012.04.008.
7. Giannousi Z., Gioulbasanis I., Pallis A.G., Xyrafas A., Dalliani D., Kalbakis K., et al. Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis. Support Care Cancer 2012, 20(8):1823-1829. 10.1007/s00520-011-1282-x.
8. McMillan D.C. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 2008, 67(3):257-262. pii:S0029665108007131. 10.1017/S0029665108007131.
9. Gebbia V., Galetta D., De Marinis F. Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials. Ann Oncol 2005, 16(Suppl. 4):iv123-iv131. 10.1093/annonc/mdi921.
10. Govindan R., Garfield D.H. Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol 2004, 31(6 Suppl. 11):27-31.
11. Fearon K., Strasser F., Anker S.D., Bosaeus I., Bruera E., Fainsinger R.L., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011, 12(5):489-495. pii:S1470-2045(10)70218-7. 10.1016/S1470-2045(10)70218-7.
12. Altman D.G., McShane L.M., Sauerbrei W., Taube S.E. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 2012, 9(5):e1001216. 10.1371/journal.pmed.1001216.
13. Wojcik E., Rychlik U., Stasik Z., Kulpa J., Reinfuss M., Skotnicki P. Prognostic value of laboratory factors of performance status in lung cancer patients. Przegl Lek 2009, 66(8):424-432.
14. Penel N., Vanseymortier M., Bonneterre M.E., Clisant S., Dansin E., Vendel Y., et al. Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs 2008, 26(1):53-58. 10.1007/s10637-007-9088-x.
15. Ando M., Ando Y., Hasegawa Y., Shimokata K., Minami H., Wakai K., et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 2001, 85(11):1634-1639. pii:0007092001921627S. 10.1054/bjoc.2001.2162.
16. Dajczman E., Kasymjanova G., Kreisman H., Swinton N., Pepe C., Small D. Should patient-rated performance status affect treatment decisions in advanced lung cancer?. J Thorac Oncol 2008, 3(10):1133-1136. pii:01243894-200810000-00008. 10.1097/JTO.0b013e318186a272.
17. Chow E., Harth T., Hruby G., Finkelstein J., Wu J., Danjoux C. How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients?. A systematic review. Clin Oncol (R Coll Radiol) 2001, 13(3):209-218.
18. Blagden S.P., Charman S.C., Sharples L.D., Magee L.R., Gilligan D. Performance status score: do patients and their oncologists agree?. Br J Cancer 2003, 89(6):1022-1027. 10.1038/sj.bjc.6601231.
19. Sorensen J.B., Klee M., Palshof T., Hansen H.H. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993, 67(4):773-775.
20. McMillan D.C. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013, 39(5):534-540. pii:S0305-7372(12)00171-5. 10.1016/j.ctrv.2012.08.003.
21. Laird B.J., Kaasa S., McMillan D.C., Fallon M.T., Hjermstad M.J., Fayers P., et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res 2013, 19(19):5456-5464. 10.1158/1078-0432.CCR-13-1066.
22. Anshushaug M., Gynnild M.A., Kaasa S., Kvikstad A., Gronberg B.H. Characterization of patients receiving palliative chemo- and radiotherapy during end of life at a regional cancer center in Norway. Acta Oncol 2014, 1-8. 10.3109/0284186X.2014.948061.